Finkelstein Thompson LLP Announces Investigation Of Affymax, Inc.

  Finkelstein Thompson LLP Announces Investigation Of Affymax, Inc.

Business Wire

WASHINGTON -- February 27, 2013

The law firm Finkelstein Thompson LLP is investigating potential claims on
behalf of shareholders of Affymax, Inc. (“Affymax” or “the Company”) (Nasdaq:
AFFY). Finkelstein Thompson’s investigation relates to the recent announcement
by Affymax and partner Takeda Pharmaceutical that they were voluntarily
recalling all lots of Omontys, Affymax’s flagship anemia drug.

Affymax’s recall allegedly resulted from reports of severe allergic reactions
in some kidney-disease patients, culminating in at least five deaths. On
Sunday, February 24, 2013, the U.S. Food and Drug Administration alerted
healthcare providers about the Omontys recall. The next day -- Monday,
February 25, 2013 -- Affymax’s share price plummeted as much as 85% from the
Friday’s close. The investigation focuses on whether Affymax violated state or
federal laws in connection with its public statements regarding Omontys’s side
effects and the subsequent recall of the drug.

If you are interested in discussing your rights as an Affymax shareholder, or
have information relating to this investigation, please contact Finkelstein
Thompson’s Washington, DC offices at (202)-337-8000 or by email at
contact@finkelsteinthompson.com.

Finkelstein Thompson LLP has spent over three decades delivering outstanding
representation to institutional and individual clients in financial
litigation, and has been appointed as lead or co-counsel in dozens of
shareholder class actions. Indeed, the firm has served in leadership roles in
cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our website at
www.finkelsteinthompson.com. Attorney advising. Prior results do not guarantee
similar outcomes.

Contact:

Finkelstein Thompson LLP
Rosalee Thomas, 202-337-8000
 
Press spacebar to pause and continue. Press esc to stop.